Grimes & Company, Inc. Vertex Pharmaceuticals Inc Transaction History
Grimes & Company, Inc.
- $3.31 Billion
- Q2 2024
A detailed history of Grimes & Company, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Grimes & Company, Inc. holds 629 shares of VRTX stock, worth $285,282. This represents 0.01% of its overall portfolio holdings.
Number of Shares
629
Previous 607
3.62%
Holding current value
$285,282
Previous $253,000
16.21%
% of portfolio
0.01%
Previous 0.01%
Shares
5 transactions
Others Institutions Holding VRTX
# of Institutions
1,708Shares Held
225MCall Options Held
1.2MPut Options Held
1.59M-
Capital World Investors Los Angeles, CA26.7MShares$12.1 Billion2.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA23MShares$10.4 Billion0.21% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$9.67 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.7MShares$5.32 Billion0.24% of portfolio
-
Capital Research Global Investors Los Angeles, CA8.54MShares$3.87 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $116B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...